510(k) Report

510(k) · Cleared

Cleared

Lyoplant Dura Substitute (Various)

K970851510(k) TraditionalCleared Dec 9, 1997277-day reviewClass II21 CFR 882.5910

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Aesculap, Inc. · GXQ Dura Substitute

Cleared on Dec 9, 1997 after a 277-day review. The FDA summary names its predicate without a number. 31 later devices descend from it.

Decided
Dec 9, 1997
Review
277 days
Class
Class II
Product code
GXQ
Recalls
None
Predicates
0

31 later devices descend from it, 3 citing it directly.

Descendants, by year cleared 1999: 1 descendant cleared2014: 1 descendant cleared2013: 3 descendants cleared2004: 4 descendants cleared2003: 2 descendants cleared2012: 2 descendants cleared2002: 1 descendant cleared2016: 2 descendants cleared2015: 3 descendants cleared2007: 2 descendants cleared2010: 1 descendant cleared2005: 2 descendants cleared2017: 2 descendants cleared2006: 2 descendants cleared2022: 1 descendant cleared2025: 2 descendants cleared1995200020052010201520202025
  1. This deviceK970851 Lyoplant Dura Substitute (Various)Aesculap, Inc. · 1997
  2. Descendant · cites it directly · 30 of its ownK982180 Duragen Dural Graft MatrixIntegra Lifesciences Corp. · 1999 · Recalled
  3. Descendant · 2 generations on · 9 of its ownK032693 Duragen Plus Dural Graft MatrixIntegra Lifesciences Corp. · 2003 · Recalled
  4. Descendant · 2 generations on · 7 of its ownK041000 Durepair Dura Regeneration MatrixMedtronic Neurosurgery · 2004
  5. Descendant · 3 generations on · 5 of its ownK052211 Durepair Dura Regeneration MatrixMedtronic Neurosurgery · 2005
  6. Descendant · 3 generations on · 3 of its ownK063117 Modification to Durepair Dura Regeneration MatrixMedtronic Neurosurgery · 2006

Showing 5 of 31 descendants. See all descendants

Descendants cleared per year

1999: 12002: 12003: 22004: 42005: 22006: 22007: 22010: 12012: 22013: 32014: 12015: 32016: 22017: 22022: 12025: 2
1999high 4 (2004) · low 0 (2000)2026

Most influential descendants

Showing 5 of 31 · See all
  • K982180Duragen Dural Graft MatrixIntegra Lifesciences Corp. · 1999 · cites it directly30descendants
  • K032693Duragen Plus Dural Graft MatrixIntegra Lifesciences Corp. · 2003 · 2 generations on9descendants
  • K041000Durepair Dura Regeneration MatrixMedtronic Neurosurgery · 2004 · 2 generations on7descendants
  • K052211Durepair Dura Regeneration MatrixMedtronic Neurosurgery · 2005 · 3 generations on5descendants
  • K063117Modification to Durepair Dura Regeneration MatrixMedtronic Neurosurgery · 2006 · 3 generations on3descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K970851Lyoplant Dura Substitute (Various)Aesculap, Inc.1997—
+1K982180Duragen Dural Graft MatrixIntegra Lifesciences Corp.19991
+2K032693Duragen Plus Dural Graft MatrixIntegra Lifesciences Corp.20031
+2K041000Durepair Dura Regeneration MatrixMedtronic Neurosurgery2004—
+3K052211Durepair Dura Regeneration MatrixMedtronic Neurosurgery2005—
+3K063117Modification to Durepair Dura Regeneration MatrixMedtronic Neurosurgery2006—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
199910
200210
200320
200440
200520
200620
200720
201010
201220
201330
201410
201530
201620
201720
202210
202520
FIG. 1 — Lineage of K970851, 1997–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GXQ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GXQ device

  1. #1 K251191 Collagen Dura Regeneration Membrane - Repairscore 12.2 · 7 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (6)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—Dura-Guard™ Dural Repair Patch
Named without a submission number
—
*—Peri-Guard® Pericardium
Named without a submission number
—
*—Neuro-Patch Dura Substitute
Named without a submission number
—
*—Preclude Dura Substitute
Named without a submission number
—
*—Dura Film
Named without a submission number
—
*—Tutoplast® Dura substitute
Named without a submission number
—

What descends from it? (31)

See all 31

3 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K982180Duragen Dural Graft MatrixIntegra Lifesciences Corp.199930
K132850Bovine Pericardium Suturable Dural Graft, Tutopatch DM Graft, Tutoplast Bovine…Rti Surgical, Inc.20140
K122791Lyoplant OnlayAesculap, Inc.20130

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K982180 (Integra Lifesciences Corp., 1999) has gone furthest, with 30 descendants of its own.

How does its category compare?

All GXQ devices

GXQ Dura Substitute: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · GXQ

2in 2025

2007: 22010: 12012: 22013: 32014: 12015: 32016: 32017: 22019: 12022: 12023: 12025: 2
2007high 3 (2013) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GXQ

94in 2016

2013: 181 days median2015: 214 days median2016: 94 days median
2007high 214 (2015) · low 94 (2016)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GXQ

2in 2024

2010: 62013: 12021: 22024: 2
2007high 6 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · GXQ

61in 2025

2007: 552008: 432009: 462010: 362011: 312012: 382013: 722014: 182015: 622016: 582017: 572018: 942019: 632020: 1142021: 762022: 592023: 1092024: 552025: 61
2007high 114 (2020) · low 18 (2014)2025

MAUDE reports naming product code GXQ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—055
20080—043
20090—046
20101—636
20110—031
20122—038
20133181172
20141—018
20153214062
2016394058
20172—057
20180—094
20191—063
20200—0114
20210—276
20221—059
20231—0109
20240—255
20252—061
20260—0—

What is it indicated for?

Lyoplant Dura Substitute presented in this submission is intended as a dura mater substitute in neurological procedures for soft tissue reconstruction of damaged, impaired, or missing tissue.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K970851: Lyoplant Dura Substitute (Various).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K970851

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026